For PacBio and ONT I am not sure. Google I guess would want to make sequencing a commodity. For illumina? Polygenic risk scores in healthcare I guess. All the public polygenic risk score predictors suck. They should change that if they want to make that space a commodity. Fund the personal genome project (the project fizzled out with 400K+ volunteers because they don’t have enough funding to sequence people!). I would also personally be interested in that, so partally motivated reasoning. But when I asked Claude to check online it tells me they make more money in healthcare than in research now.
I have no idea what innovation looks like in PRS. ML is all good but the bottleneck is (presumably) phenotyping which none of these companies want to do.
For PacBio and ONT I am not sure. Google I guess would want to make sequencing a commodity. For illumina? Polygenic risk scores in healthcare I guess. All the public polygenic risk score predictors suck. They should change that if they want to make that space a commodity. Fund the personal genome project (the project fizzled out with 400K+ volunteers because they don’t have enough funding to sequence people!). I would also personally be interested in that, so partally motivated reasoning. But when I asked Claude to check online it tells me they make more money in healthcare than in research now.
I have no idea what innovation looks like in PRS. ML is all good but the bottleneck is (presumably) phenotyping which none of these companies want to do.